NCT03672630

Phase 2/Phase 3Interventional

Trials that are a combination of phases 2 and 3.

View on ClinicalTrials.gov ↗

Timeline

Start date: Feb 28, 2019
Primary completion: Feb 28, 2023
Completion date: Feb 28, 2023
First posted: —
Last posted: —
Enrollment: 500
Arms / groups: 2 / —
Source: AACT · ingestion pipeline

Sponsors

Oregon Health and Science UniversityLead sponsor
EvergreenHealthCollaborator
Duke UniversityCollaborator
Emory UniversityCollaborator
Georgetown UniversityCollaborator
Johns Hopkins UniversityCollaborator
Louisiana State UniversityCollaborator
Mayo ClinicCollaborator
Medical University of South CarolinaCollaborator
New York UniversityCollaborator
Oregon Health and Science UniversitySponsor investigator
Oregon Health and Science UniversityStudy director
Oregon Health and Science UniversityOverall official - principal investigator
Stanford UniversityCollaborator
The Oregon ClinicCollaborator
University of Texas, TylerCollaborator
University of TorontoCollaborator
University of California, San DiegoCollaborator
University of California, San FranciscoCollaborator
University of ChicagoCollaborator
University of IowaCollaborator
University of KansasCollaborator
University of MiamiCollaborator
University of North Carolina at Chapel HillCollaborator
University of WashingtonCollaborator
Yale UniversityCollaborator
University of Colorado, DenverCollaborator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.